Next Phase Newsletter

A private investment firm launched a healthtech-dedicated fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities. 
 
The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine). 
 
The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare and life sciences focused venture capital firm with US and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Silicon Valley-based VC fund is focused on early-stage ( Seed, Series A/B ) AI companies in Healthcare, Enterprise, and Automation. With a mission-driven thesis of doing well by doing good, the firm invest in technical founders keen on applying AI to solve some of the acutest problems faced across industries. The firm is currently investing from its second fund which is focusing on applied AI for Healthcare ( Precision Medicine, AI Drug Development, Gene/Cell Therapies Delivery, Oncology, Medical Imaging, Digital Healthcare), Enterprise ( Co-Pilots for Enterprise, Cybersecurity, DevOps/MLOps Tools, Infrastructure), and Automation ( Robotics, Autonomous Driving, Drones ). 

The firm’s team is a multidisciplinary team of seasoned founders, deep technologists/scientists, and healthcare practitioners united by a drive to nurture the next wave of startups transforming lives through AI. 

The firm can invest from Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. 
 
In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 
 
The firm prefers to take a board seat however, it is not required. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is particularly interested in tech companies generating data. The firm takes a close look at amount and quality of generated data. The firm is focused on early stages, specifically Seed and Series A. The firm’s typical check size is between $1M-$5M in equity, typically investing in 20 companies each year. The firm is focused on USA based companies. 
 
The firm is focused on digital health and techbio (typically looked at as the intersection of life sciences and AI). Previous investments include single-cell protein sequencing, a company using AI for tech-enabled drug discovery, and a company developing mRNA Therapeutics for Cancers. The firm has no revenue requirements for companies. 
 
The firm can both lead and co-invest and will consider a board seat on a case-by-case basis. The firm has no requirements for the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A newly established angel investor group headquartered in the US with ties/members in China is looking for innovative opportunities in the healthcare sector. The firm invest in early stages, including seed and series A, The firm’s typical check size ranges from $100K – $500K. The firm is open to USA based companies. 
 
The firm is primarily focused on investing in digital health and medical devices. The firm is indication- and modality- agnostic. 
 
The firm is open to both co-investing and leading, though prefers to co-invest. The firm likes with see a management team from a relevant domain with previous business experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare investment arm of a multi-strategy asset management firm focuses on early-stage opportunities in the medical device and digital health sectors, having invested approximately $250M USD in healthcare and medtech. The firm typically engages in Series A rounds and beyond, with check sizes ranging from $5M to $20M USD, and follow-on investments are a possibility. While the firm primarily focuses on the US (especially the Bay Area) and Europe, it remains open to global opportunities. 
 
The firm primarily considers opportunities in medical devices and digital health. Traditional asset-driven therapeutics are out of scope. The firm is agnostic to subsectors and indications but prefers disease areas with large addressable markets and companies with a clear reimbursement strategy. Some areas of interest include cardiovascular, ophthalmology, and diabetes. The fund typically evaluates clinical-stage opportunities but is open to considering design-stage companies, provided they have strong validation. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers founders with experience or a successful track record. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm manages funds for a major health insurance company in the US. The firm seeks to invest in healthcare companies of strategic interest to this insurance company while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in insurtech companies. The firm partners with payers and providers to drive innovation in healthcare, with a focus in medical devices, diagnostics, and AI solutions for providers. 
 
Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices. 
 
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.